Study Comparing Combined and Separate Tablets of Enlicitide and Rosuvastatin in Healthy Adults Ages 18 to 55

What this Trial Is About

Researchers are evaluating two medicines, enlicitide and rosuvastatin, in healthy adults aged 18 to 55 years. The study aims to compare the amounts of these medicines in the body over time when given separately and when combined into a single tablet. This research is a Phase 1 trial focused on basic science to understand how these drugs behave when taken together or alone. Participants will receive either a single dose of enlicitide with rosuvastatin tablets taken together or a single dose of a combined tablet called MK-0616A or its formulation B. The study includes two parts where these treatments are given in a randomized crossover design, meaning participants receive different treatments in sequence to compare drug absorption. During the study, participants will be monitored for drug levels in their blood at specific times up to 168 hours after dosing. Researchers will measure how much of each drug is present over time and the highest concentration reached. Safety will also be evaluated by tracking any side effects or adverse events during the approximately nine weeks of observation. Participants will have scheduled visits for dosing and blood sampling throughout the study period.

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)